← Leaderboards

Mary V. Relling

St. Jude Children'S Research Hospital

Google Scholar ↗PubMed ↗ORCID ↗

$28,942,987

Attributed

$31,252,491

Total exposure

13

Grants

10

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.3M · FY2005–20

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

Funding mix

By agency

NIH$46,380,371 · 14

By mechanism

P50$18,067,756 · 3

U01$13,899,725 · 4

R01$7,288,468 · 2

R24$3,619,010 · 1

RC4$1,731,842 · 1

U24$999,999 · 1

Top collaborators

Mignon Lee-Cheun Loh6 shared
Teri Ellen Klein4 shared

Most similar at St. Jude Children'S Research Hospital

Same institution · by research overlap

William E. Evans$20,051,064
Jun J. Yang$13,116,250

Others in their field

Top investigators on “Clinical Trials”

Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
Sonia M Thomas · Research Triangle Institute$700,865,642
David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
Bambra Strokes · Ppd Development Lp$526,656,217
Judith S. Currier · University Of California Los Angeles$504,273,077

Research focus

Clinical TrialsPhenotypeLeukemiaToxic EffectGenomicsRelapseGlucocorticoidsLeukemia, Lymphocytic, Acute, L1PharmacogenomicsPharmaceutical PreparationsAdverse EffectsMethotrexateResponseAdultChildVariantRegimenThiopurineMalignant NeoplasmsBone NecrosisPublic Health RelevanceAsparaginaseAcute Lymphocytic LeukemiaResearch Personnel

Grant awards (65)

Glucocorticoids in Lymphoblastic Leukemia$487,994

R01 · FY2020 · CA · contact PI

Pharmacokinetics Shared Resources Core$289,295

P30 · FY2020 · CA · contact PI

Center for Precision Medicine in Leukemia (CPML)$2,918,766

P50 · FY2019 · GM · contact PI

Glucocorticoids in Lymphoblastic Leukemia$473,354

R01 · FY2019 · CA · contact PI

CPML - Project 3: Genome-wide Studies of Adverse Effects$351,828

P50 · FY2019 · GM · contact PI

Pharmacokinetics Shared Resources Core$280,006

P30 · FY2019 · CA · contact PI

CPML - Core A: Administrative Core$204,480

P50 · FY2019 · GM · contact PI

Center for Precision Medicine in Leukemia (CPML)$3,040,119

P50 · FY2018 · GM · contact PI

Clinical Pharmacogenetics Implementation Consortium (CPIC)$999,999

U24 · FY2018 · HG · contact PI

Glucocorticoids in Lymphoblastic Leukemia$487,994

R01 · FY2018 · CA · contact PI

CPML - Project 3: Genome-wide Studies of Adverse Effects$384,126

P50 · FY2018 · GM · contact PI

CPML - Core A: Administrative Core$212,409

P50 · FY2018 · GM · contact PI

Center for Precision Medicine in Leukemia (CPML)$2,964,251

P50 · FY2017 · GM · contact PI

Clinical Pharmacogenetics Implementation Consortium (CPIC)$1,198,877

R24 · FY2017 · GM · contact PI

Glucocorticoids in Lymphoblastic Leukemia$487,994

R01 · FY2017 · CA · contact PI

CPML - Project 3: Genome-wide Studies of Adverse Effects$369,780

P50 · FY2017 · GM · contact PI

CPML - Core A: Administrative Core$204,478

P50 · FY2017 · GM · contact PI

Center for Precision Medicine in Leukemia (CPML)$96,271

P50 · FY2017 · GM · contact PI

Center for Precision Medicine in Leukemia (CPML)$2,969,744

P50 · FY2016 · GM · contact PI

Clinical Pharmacogenetics Implementation Consortium (CPIC)$1,198,877

R24 · FY2016 · GM · contact PI

Glucocorticoids in Lymphoblastic Leukemia$485,955

R01 · FY2016 · CA · contact PI

CPML - Project 3: Genome-wide Studies of Adverse Effects$384,140

P50 · FY2016 · GM · contact PI

CPML - Core A: Administrative Core$204,478

P50 · FY2016 · GM · contact PI

Center for Precision Medicine in Leukemia (CPML)$3,138,729

P50 · FY2015 · GM · contact PI

Clinical Pharmacogenetics Implementation Consortium (CPIC)$1,221,256

R24 · FY2015 · GM · contact PI

CPML - Project 3: Genome-wide Studies of Adverse Effects$401,364

P50 · FY2015 · GM · contact PI

CPML - Core A: Administrative Core$222,793

P50 · FY2015 · GM · contact PI

PAAR4Kids-Pharmacogenomics of Anticancer Agents Research in Children$1,835,847

U01 · FY2014 · GM · contact PI

Glucocorticoids in Lymphoblastic Leukemia$377,484

R01 · FY2014 · CA · contact PI

PAAR4Kids-Pharmacogenomics of Anticancer Agents Research in Children$1,776,954

U01 · FY2013 · GM · contact PI

Glucocorticoids in Lymphoblastic Leukemia$363,320

R01 · FY2013 · CA · contact PI

Glucocorticoids in Lymphoblastic Leukemia$93,607

R01 · FY2013 · CA · contact PI

PAAR4Kids-Pharmacogenomics of Anticancer Agents Research in Children$1,563,234

U01 · FY2012 · GM · contact PI

Glucocorticoids in Lymphoblastic Leukemia$383,964

R01 · FY2012 · CA · contact PI

PAAR4Kids-Pharmacogenomics of Anticancer Agents Research in Children$278,021

U01 · FY2012 · GM · contact PI

Glucocorticoids in Lymphoblastic Leukemia$99,582

R01 · FY2012 · CA · contact PI

PAARK4Kids-Pharmacogenomics of Anticancer Agents Research in Children$1,575,077

U01 · FY2011 · GM · contact PI

Glucocorticoids in Lymphoblastic Leukemia$381,515

R01 · FY2011 · CA · contact PI

Glucocorticoids in Lymphoblastic Leukemia$28,823

R01 · FY2011 · CA · contact PI

PAARK4Kids-Pharmacogenomics of Anticancer Agents Research in Children$1,827,001

U01 · FY2010 · GM · contact PI

Pharmacogenomics of Racial Disparities in Childhood Leukemia Outcomes$1,731,842

RC4 · FY2010 · CA · contact PI

Glucocorticoids in Lymphoblastic Leukemia$435,991

R01 · FY2010 · CA · contact PI

Acute Lymphoblastic Leukemia$462,503

U01 · FY2009 · GM · contact PI

Acute Lymphoblastic Leukemia$469,989

U01 · FY2008 · GM · contact PI

Acute Lymphoblastic Leukemia$499,139

U01 · FY2007 · GM · contact PI

Anticancer Agent Pharmacodynamics in Acute Leukemia$498,489

R01 · FY2006 · CA · contact PI

Acute Lymphoblastic Leukemia$356,892

U01 · FY2006 · GM · contact PI

Anticancer Agent Pharmacodynamics in Acute Leukemia$496,004

R01 · FY2005 · CA

Acute Lymphoblastic Leukemia$356,892

U01 · FY2005 · GM

Anticancer Agent Pharmacodynamics in Acute Leukemia$501,228

R01 · FY2004 · CA

Anticancer Agent Pharmacodynamics in Acute Leukemia$468,296

R01 · FY2003 · CA

Anticancer Agent Pharmacodynamics in Acute Leukemia$460,757

R01 · FY2002 · CA

CORE--LIVER BANK$362,272

U01 · FY2002 · GM

CORE--LIVER BANK$362,272

U01 · FY2002 · GM

CYP3A4 GLUCURONIDATION OF EPIRUBICIN$362,272

U01 · FY2002 · GM

CYP3A4 GLUCURONIDATION OF EPIRUBICIN$362,272

U01 · FY2002 · GM

CORE--PHARMACOKINETICS$0

P30 · FY2002 · CA

CORE--PHARMACOKINETICS SHARED RESOURCE$0

P30 · FY2002 · CA

CYP3A4 GLUCURONIDATION OF EPIRUBICIN$362,272

U01 · FY2001 · GM

CORE--LIVER BANK$362,272

U01 · FY2001 · GM

CORE--PHARMACOKINETICS SHARED RESOURCE$0

P30 · FY2001 · CA

CORE--LIVER BANK$362,272

U01 · FY2000 · GM

CYP3A4 GLUCURONIDATION OF EPIRUBICIN$362,272

U01 · FY2000 · GM

P450 METABOLISM OF EPIPODOPHYLLOTOXINS IN CHILDREN$276,117

R01 · FY2000 · CA

CORE--PHARMACOKINETICS SHARED RESOURCE$204,270

P30 · FY2000 · CA